Case Report

Acute Promyelocytic Leukemia in a Woman with Thalassemia Intermedia: Case Report and Review of Literature on Hematological Malignancies in β-Thalassemia Patients

Claudio Pellegrino 1,2,* Giulia Dragonetti 1, Patrizia Chiusolo 1,2, Monica Rossi 1, Nicoletta Orlando 1 and Luciana Teofili 1,2

1 Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, I-00168 Roma, Italy
2 Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, I-00168 Rome, Italy
* Correspondence: claudiopellegrino94@gmail.com; Tel.: +06-30156016

Abstract: Patients affected by transfusion-dependent β-thalassemia are prone to developing several clinical complications, mostly related to the iron overload. We report the case of a patient affected by transfusion-dependent β-thalassemia (TDT) developing acute promyelocytic leukemia (APL). In our case, the therapeutic management was significantly complicated not only by myocardial dysfunction, but also by the occurrence of the differentiation syndrome following all-trans retinoic acid (ATRA) administration. We carried out a careful revision of the current literature on the occurrence of hematological malignancies in β-thalassemia patients to investigate the major complications so far described. APL occurrence in β-thalassemia patients has been very rarely reported, and our experience suggests that TDT patients suffering pre-existing comorbidities may develop a potentially fatal complication during ATRA therapy.

Keywords: acute promyelocytic leukemia; β-thalassemia; hematological malignancies; retinoic acid; ATRA differentiation syndrome

1. Introduction

β-thalassemia syndromes are a group of hereditary disorders characterized by a genetic deficiency in the synthesis of β-globin chains, resulting in accumulation and deposition of unpaired α-globin chains in red blood cells (RBCs). This causes hemolysis and ineffective hematopoiesis leading to chronic anemia. Currently, the availability of proper care and appropriate treatment strategies, including regular transfusions, allogeneic stem cell transplantation, inducers of fetal hemoglobin synthesis, and iron chelation therapy, have resulted in increased life expectancy and quality of life in patients suffering from β-thalassemia major. The prolonged life span increases the possibility that other diseases such as malignancies may occur, possibly due to the iron-overload-induced oxidative stress in bone marrow microenvironment, and the increased hematopoietic drive [1]. In this study we report the case of a patient affected by transfusion-dependent β-thalassemia developing acute promyelocytic leukemia (APL).

In our case, complications related to the β-thalassemia significantly hampered the management of the APL treatment. Therefore, we carefully reviewed current literature to investigate whether other authors had previously reported APL occurrence in this setting. Moreover, we explored whether the underlying β-thalassemia affected the therapy management of hematological malignancies, finally worsening the prognosis of these patients.

2. Case Report

A 69-year-old woman was tracked as an outpatient for a β-thalassemia intermedia, due to the HBB gene heterozygous mutation c.92 + 1G > A (rs33971440, VAF 48.73) and
a duplication triple α anti 3.7 (αααanti3.7). At her first visit to our hospital, she was aged 49 years and had been receiving occasional transfusions, mainly in association with concomitant infectious episodes. She was positive for both HBV and HCV hepatitis viruses. The patient was gradually shifted to a regular transfusion regimen for progression of splenomegaly, worsening anemia, and appearance of formations compatible with extramedullary hematopoiesis (EMH) in the para-vertebral region (38 × 17 mm). She was given iron chelation therapy, first with deferoxamine and then with deferasirox. Since MRI for iron overload estimation was not available at our hospital, the patient had no quantitative assessment, and iron chelation therapy was administered according to ferritin levels.

The transfusion management was complicated by the development of anti-E allo-immunization and cold agglutinins. The patient was treated for HBV infection with Entecavir and for HCV infection with direct-acting antivirals: at last hepatology visit, an HBV-related hepatic cirrhosis was documented (liver stiffness 9.7 kPa, Metavir F3) with portal hypertension (without ascites or history of upper gastrointestinal bleeding). She was also suffering from asthma-chronic pulmonary obstructive disease (CPOD) overlap syndrome and bronchiectasis. Moreover, she had an episode of non-valvular atrial fibrillation in 2018, and was successfully subjected to cardioversion with amiodarone. Other significant comorbidities included osteoporosis with a history of bilateral wrist fractures, recurrent superficial thrombophlebitis, and anxious-depressive syndrome.

In May 2021, the patient underwent total knee arthroplasty surgery and was subsequently admitted to a rehabilitation ward. During the post-operative course, the blood cell count (CBC) showed a progressive decrease in platelet and neutrophil count. The CBC at nadir documented WBC 3.4 × 10^9, platelets 24 × 10^9/L, with the smear examination showing 34% of lymphocytes, 6% of monocytes, 26% of neutrophils, 5% of granulocyte precursors, and 27% blast cells. A marked dysplasia of the granulocytic series was also documented. Blast morphology was reminiscent of abnormal promyelocytes [2] (Figure 1A). Physical examination was unremarkable except for the presence of palpable hepatosplenomegaly. Bone marrow blood smear showed a marked (56%) infiltration of myeloid peroxidase positive blast and abnormal promyelocytes (Figure 1B). Flow cytometry reported a blastic myeloid population CD117 + CD34 +/− CD13 + CD33 ++ HLA–DR − accounting for 71% of the total bone marrow cellularity. Molecular analysis with nested RT–PCR revealed a bcr3 isoform of the promyelocytic leukemia/retinoic acid receptor alpha (PML–RARA) transcript and a FLT3 ITD.

Based on the aforementioned exams, diagnosis of intermediate risk acute promyelocytic leukemia was made [3] and the patient started an induction therapy with all-trans retinoic acid (ATRA) 60 mg/die and idarubicin 7.45 mg (5 mg/m^2) for four consecutive days, in association with methylprednisolone 20 mg/die for the prevention of the differentiation syndrome [4].

The patient’s clinical course is summarized in Figure 2. Starting from the fourth day of ATRA administration, we assisted a rise in WBC count, associated with the development of peripheral edema, dyspnea and oxygen desaturation. A chest X-ray revealed bilateral pulmonary infiltrates and an enlarged cardiac shadow with pleural effusion (Figure 3). On the suspicion of ATRA differentiation syndrome (DS), ATRA was temporarily discontinued, and two boli of cytarabine 500 mg were administered to rapidly lower the WBC count; moreover, methylprednisolone was switched to dexamethasone 20 mg/die, and oxygen supplementation was started. Clinical management was further complicated by the development of atrial fibrillation with rapid ventricular response, successfully cardioverted with amiodarone.
Figure 1A. Upper picture: peripheral blood smear, showing anisopoikilocytosis, microcytic hypochromic red cells, and numerous target cells. In the center, a leukemic promyelocyte (black arrow). (B) Lower picture: bone marrow blood smear, showing promyelocytes (black arrows) and marked dyserythropoiesis (red arrow).

On day 9, given the improvement in clinical condition and the lowered peripheral WBC count, ATRA therapy was resumed at full dosage. During the subsequent three days, the patient’s condition worsened, with dyspnea, respiratory rate up to 30 breaths per minute, recurrent episodes of hemoptysis and peripheral blood oxygen desaturation. A bronchoalveolar lavage (BAL) was achieved, positive for Pseudomonas Aeruginosa and CMV genome (4445 copies/mL). Retinoic acid was suspended, and ventilatory support with nasal high flow therapy (Optiflow™, 60 L/min) was started, in association with diuretic (furosemide in continuous infusion) and an antimicrobial therapy (meropenem,
amikacin, liposomal amphotericin B and foscarnet). The progressive improvement of pulmonary function prompted the reintroduction of ATRA on day 18 (Figure 2). Even this third attempt was unsuccessful, as during the subsequent days the patient rapidly developed signs of severe differentiation syndrome, including weight gain of up to 20 kilos, acute renal failure, and dyspnea with radiological evidence of bilateral pulmonary infiltrates, consolidation, and pleural effusion. The clinical course was further complicated by three episodes of atrial fibrillation, all successfully managed with pharmacological cardioversion. Liquid restriction, diuretic therapy, albumin replacement, ATRA discontinuation and pleural effusion produced a clear benefit. On day 40, ATRA therapy at lower doses (30 mg/day) was finally restarted. On day 47 the patient was finally dismissed.

**Figure 2.** Gantt graph displaying patient’s clinical course during the treatment of acute promyelocytic leukemia (Office Timeline.Version 6.00.06, 2021 Office Timeline Inc., Bellevue WA 98004, USA). AF: atrial fibrillation; ATRA: all trans-retinoid acid; VM: Ventimask.

**Figure 3.** Chest X-ray and TC scan documenting bilateral pulmonary infiltrates and pleural effusion during ATRA differentiation syndrome (Carestream Vue Motion Version 12.1.5.9529 © Carestream Health, Inc., Rochester, NY, USA, 2021). D: RIGHT side.
The bone marrow examination performed on day 70 displayed a complete morphological response and the absence of the PML/RAR-\(\alpha\) transcript was documented. Due to several comorbidities, no further chemotherapy was administered, and the patient was offered a palliative care program.

3. Systematic Review of Studies on \(\beta\)-Thalassemia and Hematological Malignancies

Hepatic cancer is the neoplasia most frequently occurring in \(\beta\)-thalassemia patients due to the liver iron overload. Hematological neoplasms and other solid cancers have seldom been reported and attributed to the chronic stress in the bone marrow and to iron overload [1]. We conducted a systematic review on the occurrence of hematological malignancies in \(\beta\)-Thalassemia, with a special focus on acute leukemia. The reporting of this systematic review was guided by the standards of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement, when applicable.

We performed a systematic search on the PubMed database using the following queries: “\(\beta\)-Thalassemia” [Mesh] AND “Neoplasms” [Mesh]. No additional search filters were applied. C.P and L.T independently controlled all references, including case reports, case series, and reviews. Discrepancies were discussed and resolved together.

Up to June 2021, 252 total references were identified. We excluded papers reporting solid neoplasm and extra-medullary hematopoietic masses mimicking solid neoplasms, papers reporting secondary neoplasms after hematopoietic stem cell transplantation, papers reporting patients with hemoglobinopathies other than \(\beta\)-thalassemia/HbE, communications at congresses, papers reporting hematological neoplasms in \(\beta\)-Thalassemia minor, duplicated studies, and papers with an abstract not in English. In the end, 25 papers were included in the review. Collected data included study type, patient characteristics, type and clinical presentation of hematological malignancy, therapy, and outcome. Results are shown in Table 1.
Table 1. Studies reporting the occurrence of hematological malignancies in transfusion dependent and independent β-thalassemia patients.

| Malignancy | Reference | Patients (n) | Sex/Age | Hemoglobinopathy | Splenectomy | Clinical Presentation | Therapy/Outcome |
|------------|-----------|--------------|---------|-------------------|-------------|-----------------------|-----------------|
| HL         | Balestrazzi and Butturini, 1985 [5] | 1 | M/10 | BTM | ND | Lymphocyte rich cHL (CS II2B) | 6MOPP + RT DF at 3 years |
|            | Thapa et al., 2009 [6] | 1 | F/7 | BTM | No | Mixed cellularity cHL, stage IV | 6 COPP, Complete remission |
|            | Jabr et al., 2006 [7] | 1 | M/28 | BTI | No | Mixed cellularity cHL, IIIa | ABVD, complete remission |
|            | Ahad-Aziz Qureshi et al., 2019 [8] | 1 | M/21 | BTM | Yes | Lymphocyte-rich cHL | Not reported |
|            | Tozzi-Cecchetti, 1979 et al. [9] | 1 | M/11 | BTM | No | Diffuse follicular center lymphoma | 1 VMP, Death at 3 months |
|            | Schilirò et al., 1979 [10] | 1 | M/4 | BTM | No | NHL with bone marrow and CNS involvement. | 1 HOP + 2 IT-MTX + prophylactic CI. Death after relapse. |
|            | Otrock et al., 2006 [11] | 1 | F/25 | BTM | No | DLBCL | 4 CNOP + RT. Complete remission, 6 years’ follow-up |
|            | Ricchi et al., 2004 [12] | 1 | F/35 | BTM, HCV+ | Yes | Systemic High-grade NHL with cardiac localization | 3 RTX + surgery. Death for hemopericardium with cardiac tamponade |
|            | Triantos et al., 2013 [13] | 1 | ND | BTM | ND | NHL | Not reported |
|            | Chehal et al., 2002 [14] | 1 | F/62 | BTI | No | Large B cell lymphoma with bone marrow involvement | 6 CVP + 4 RTX. Complete remission |
| ALL        | Tuğcu et al., 2014 [15] | 1 | M/12 | BTI | No | B-ALL | Chemotherapy Complete remission |
|            | Kottaridis et al., 2000 [16] | 1 | M/34 | BTM | No | T-ALL | Chemotherapy + allo-HSCT Complete remission at 1 year |
|            | Goyal et al., 2018 [17] | 1 | M/22 | BTM | No | ALL in the context of HIV and HTLV-I infection | Death before treatment |
|            | Sherief et al., 2015 [18] | 1 | M/11 | BTM, HCV+ | No | B-ALL | Chemotherapy Complete remission |
|            | Palomo-Colli et al., 2018 [19] | 1 | M/6 | BTM | Yes | ALL-L1, B phenotype | Chemotherapy CNS radiotherapy 7y in Complete remission |
|            | Felici et al., 1988 [20] | 1 | M/6 | BTM | No | AML-M4 | Chemotherapy Death 10d after induction |
| AML        | Romani et al., 2007 [21] | 1 | M/32 | BTM, HCV+ | No | APL | ATRA+ idarubicine (induction) ATRA + idarubicine + ara-c (consolidation) Death for liver failure |
### Table 1. Cont.

| Malignancy               | Reference                      | Patients (n) | Sex/Age | Hemoglobinopathy | Splenectomy | Clinical Presentation                                                                 | Therapy/Outcome                                                                                     |
|--------------------------|--------------------------------|--------------|---------|------------------|-------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Histiocytic disorder     | De Soccio et al., 2020 [22]    | 1            | F/4     | BTM              | No          | Solitary xantogranuloma of the hypopharynx and cutaneous mastocytosis                  | Surgery. Complete remission at 11 months                                                             |
| MM                       | Arora & Ganapathi, 2020 [23]   | 1            | M/46    | BTI              | ND          | IgG lambda myeloma                                                                    | Not reported                                                                                       |
| MPN                      | Voskaridou et al., 2002 [24]   | 1            | M/32    | BTI              | Yes         | BCR/ABL+ CML with marked thrombocytosis                                                | Hydroxyurea + Anagrelide                                                                           |
|                          | Wu et al., 2020 [25]           | 1            | F/24    | BTI              | Yes         | ET                                                                                     | Observation                                                                                       |
|                          | Alavi et al., 2013 [26]        | 2            | F/16    | BTM, HCV+        | No          | HL nodular sclerosis, IIa                                                              | 6 alternating MOPP/ABVD + RT; CR at 10y Imatinib, CT. Death at 3 months                             |
|                          |                                |              | F/13    | BTI              | No          | CML, progressed to AML                                                                |                                                                                                |
|                          | Benetatos et al., 2008 [27]    | 2            | M/37    | BTI, HCV+        | Yes         | Marginal zone lymphoma, IIIa                                                          | Watch and wait. Stable disease at 2y ABVD complete remission                                        |
|                          |                                |              | F/52    | BTI              | No          | Nodular lymphocytic predominant HL IIIa                                                  |                                                                                                |
| Various                  | Karimi et al., 2009 [28]       | 10           | M/10    | BTM              | Yes         | cHL                                                                                   | Chemotherapy                                                                                      |
|                          |                                |              | M/6     | BTM              | No          | cHL                                                                                   | Chemotherapy                                                                                      |
|                          |                                |              | M/20    | BTM, HCV+        | No          | CML                                                                                   | Chemotherapy                                                                                      |
|                          |                                |              | M/16    | BTM              | Yes         | ALL-preB                                                                             | Chemotherapy                                                                                      |
|                          |                                |              | M/6     | BTI              | Yes         | AML-M4                                                                               | Chemotherapy                                                                                      |
|                          |                                |              | M/12    | BTI              | No          | ALL-T                                                                                | Chemotherapy                                                                                      |
|                          |                                |              | M/23    | BTM, HCV+        | Yes         | DLBCL                                                                                | Chemotherapy                                                                                      |
|                          |                                |              | F/28    | BTM, HCV+        | Yes         | ALL-T                                                                                | Chemotherapy                                                                                      |
|                          |                                |              | M/25    | BTM, HCV+        | Yes         | NHL                                                                                   | Chemotherapy                                                                                      |
|                          |                                |              | F/24    | BTM              | Yes         | cHL                                                                                   | Chemotherapy                                                                                      |
|                          | Zurlo et al., 1989 [29]        | 5            | ND      | BTM              | ND          | 2 NHL; 2 ALL; 1 AML                                                                   | Not reported                                                                                      |

Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Acute promyelocytic leukemia (APL), all trans retinoid acid (ATRA), Beta thalassemia major (BTM), beta thalassemia intermedia (BTI), classical Hodgkin lymphoma (cHL), Chronic myeloid leukemia (CML), Diffuse large B cell lymphoma (DLBCL), Essential thrombocythemia (ET), Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL), Multiple myeloma (MM), myeloproliferative neoplasm (MPN).
4. Discussion

The low number of cases so far described suggests that β-thalassemia does not predispose patients to hematological malignancies: the most frequent reported was NHL, strictly followed by HL, ALL, and MPN. Whether the occurrence of these hematological malignancies is the result of some kind of interaction rather than a pure coincidence remains speculative: iron, transfusion-transmitted viruses, immunosuppression secondary to blood transfusion, and hematopoietic drive can all theoretically contribute to an increase in this risk [30]. A nationwide retrospective cohort study from Taiwan showed that patients with thalassemia exhibited a 5.32-fold higher risk of developing lymphoma or leukemia than the control cohorts. In particular, transfusion-dependent thalassemia patients were 9.31-fold more likely to develop a hematologic malignancy than non–transfusion-dependent patients [31]. However, only large international multicenter studies including patients treated according to current standards and accessing novel therapies could definitively clarify this issue.

It is conceivable that especially elderly β-thalassemia patients, not treated according to current therapy standards, may develop numerous complications, including cardiopulmonary dysfunction, liver diseases, splenomegaly, endocrinopathies, and thromboses. All these complications may confound the diagnosis and hamper clinical management and treatment of the associated hematological neoplasia. The diagnosis of a hematological malignancy appears to be challenging in this peculiar population: for example, polycythemia vera tends to be masked because of the antagonizing hematological effects, one blunting the effect of the other. Moreover, the presence of some overlapping features between β-thalassemia and malignancies such as a pre-existing splenomegaly, anemia, fatigue, and infection susceptibility tends to delay diagnosis, thus worsening prognosis. Importantly, there was no significant difference in the reported toxicity profile of chemotherapy in comparison to non-thalassemic patients, except for a higher need of packed red blood cell transfusions [6].

To the best of our knowledge there is only one report in literature of a concomitant diagnosis of β-thalassemia and APL: a 32-year-old man affected by transfusion dependent HCV positive β-thalassemia major, complicated by iron overload-related cardiomyopathy, who developed a low-risk APL with t(15;17) [21]. He achieved hematological complete remission with persisting PML/RAR-α positivity after an induction course with ATRA and idarubicin: unfortunately, he died of cardiac complications. In an analogy to our case, the chemotherapy-sensitive myocardium status in thalassemia suggest caution in the use of cardiotoxic drugs (anthracycline, arsenic trioxide) in this fragile population, with a complete baseline cardiac function evaluation and a strict monitoring during therapy. Accordingly, our patient was deemed unfit to receive arsenic trioxide despite the intermediate risk of APL.

One of the most striking features of our patient was the susceptibility to developing pulmonary disease following ATRA exposure. The DS presents with acute respiratory distress, weight gain, unexplained fever, interstitial pulmonary infiltrates, pleural/pericardial effusions, hypotension, and acute renal failure. It is reported to occur during induction in 2.5% to 31% of APL patients and is associated with 15% of induction deaths [32]. Higher peripheral blood blast counts on admission as well as higher body mass index are the most consistently reported risk factors for DS development [33]. The pathogenesis of APL DS is complex and not completely elucidated: the key effects of ATRA include the release of a variety of cytokines and pro-inflammatory mediators by differentiating blast cells and the induction of a change in adhesive properties on blast cells. The combination of a systemic inflammatory state with increased vascular permeability caused by endothelial damage results in hypotension and organ hypo-perfusion, which can ultimately lead to a multi-organ failure [34].

Basically, β-thalassemia itself is associated with endothelial activation and dysfunction, coagulation abnormalities, and chronic inflammation, all leading to arterial or venous thrombosis, pulmonary hypertension, and cerebrovascular events. [35,36]. The risk
increases with aging, splenectomy, and transfusion burden [35,36]. Cellular and molecular mechanisms include red blood cells’ membrane alterations, increased platelets aggregation, and elevation in extracellular vesicles [37]. It is therefore plausible that this peculiar milieu may predispose patients to DS development, especially in pulmonary circulation, particularly susceptible to the thalassemia-induced damage. In fact, β-thalassemia patients display higher levels of markers for endothelial activation such as sICAM-1, sVCAM-1, HMGB1, and P- and E-selectins, reflecting a baseline pro-adhesive phenotype of endothelial cells [38–40]. Likewise, treatment with ATRA promotes a striking up-regulation of adhesion molecules on APL blast cells such as CD11b, CD11c, CD15, CD65, and CD54, thus leading to lung infiltration and inflammation [41–43]. Finally, there is a significant elevation of chemokine levels (CXCL1, CXCL9, CXCL10, and CXCL12) in TD β-thalassemia patients [44], while ATRA differentiation therapy can itself induce chemokine production in the lungs and chemokine receptors expression in APL cells, triggering migration of leukemic cells [45].

It should be also considered that ATRA-driven granulocytic differentiation involves the reprogramming of over 300 molecular pathways through the modulation of several transcriptional factors [46]. Among them, PU.1 is crucial for normal hematopoiesis and terminal differentiation of granulocytes, and has a well-established role in leukemia suppression [47]. PU.1 expression is suppressed in APL and restored by ATRA. Of note, dysfunctional features of granulocytes in β-thalassemia patients have been ascribed to a reduced expression of PU.1, as a result of iron overload, leading to reduced oxidative burst activity, and elevated levels of membrane lipid peroxidation [48,49]. Indeed, we could also speculate that ATRA action may be altered in β-thalassemia patients developing APL, given the pre-existing impaired myeloid terminal differentiation due to PU.1 deficiency.

5. Conclusions

The occurrence of hematological neoplasms in β-thalassemia patients has been linked to the chronic stress in the bone marrow, iron overload and transfusion transmitted viruses. Nevertheless, an increased risk has not yet been incontrovertible demonstrated. In any case, thalassemia related complications as cardiopulmonary dysfunction, liver disease and splenomegaly tend to hamper the diagnosis and treatment of the malignancies, especially in older patients. Here we reported a case of APL in a β-thalassemia woman: considering the rarity of this concomitance, with only another case reported in literature, the most plausible conclusion is that the two events are purely coincidently. However, this ominous duo poses a particular challenge to clinicians, as these patients may be prone to develop cardiac toxicity during therapy and ATRA DS. We therefore recommend caution in the use of cardiotoxic drug (anthracycline, arsenic trioxide), with a baseline cardiac evaluation and a strict monitoring during therapy, especially in patients with a pre-existing thalassemia-related cardiomyopathy. Moreover, attention should be paid at early signs of DS, like dyspnea, fever, weight gain and appearance of radiographic opacities. Further research is needed to shed light on the complex biology of these two diseases to improve clinical management of this population.

Author Contributions: Conceptualization, C.P. and L.T.; writing—original draft preparation, C.P.; writing—review and editing, C.P., L.T., P.C., M.R., G.D. and N.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: In our institute we do not require ethics committee approval for case reports.

Informed Consent Statement: According with the Italian regulation, patient consent was waived because the manuscript was written after the patient died and several attempts to contact the only living relative were unsuccessful (https://www.garanteprivacy.it/home/docweb/-/docweb-display/docweb/1878276, accessed on 18 May 2022).
Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

Atrial fibrillation (AF), Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Acute promyelocytic leukemia (APL), all trans retinoid acid (ATRA), Beta thalassemia major (BTM), beta thalassemia intermedia (BTI), classical Hodgkin lymphoma (cHL), Chronic myeloid leukemia (CML), Diffuse large B cell lymphoma (DLBCL), Essential thrombocythemia (ET), Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL), high-performance liquid chromatography (HPLC), Multiple myeloma (MM), myeloproliferative neoplasm (MPN), next generation sequencing (NGS), non-transfusion-dependent thalassemia (NTDT), transfusion-dependent thalassemia (TDT), variant allele frequency (VAF), Ventimask (VM).

References

1. Taher, A.T.; Cappellini, M.D. How I manage medical complications of b-thalassemia in adults. Blood 2018, 132, 1781–1791. Available online: http://ashpublications.org/blood/article-pdf/132/17/1781/1468099/blood818187.pdf (accessed on 18 May 2022). [CrossRef]
2. Mufti, G.J.; Bennett, J.M.; Goasguen, J.; Bain, B.J.; Baumann, I.; Brunning, R.; Cazzola, M.; Fenaux, P.; Germoing, U.; Hellström-Lindberg, E. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008, 93, 1712–1717. Available online: https://haematologica.org/article/view/5076 (accessed on 18 May 2022). [CrossRef] [PubMed]
3. Sanz, M.A.; Fenaux, P.; Tallman, M.S.; Estey, E.H.; Löwenberg, B.; Naoe, T.; Lengfelder, E.; Döhner, H.; Burnett, A.K.; Chen, S.-J.; et al. Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019, 133, 1630–1643. Available online: https://pubmed.ncbi.nlm.nih.gov/30803991/ (accessed on 18 May 2022). [CrossRef] [PubMed]
4. Lo-Coco, F.; Avvisati, G.; Vignetti, M.; Breccia, M.; Gallo, E.; Rambaldi, A.; Paoloni, F.; Fioriti, G.; Ferrara, F.; Specchia, G.; et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010, 116, 3171–3179. [CrossRef]
5. Balestazzi, P.; Butturini, A. Thalassemia and Hodgkin lymphoma. Blut 1985, 50, 55. [CrossRef]
6. Thapa, R.; Pal, P.K.; Mukhopadhayay, M. Beta Thalassemia Major and Hodgkin Lymphoma. J. Pediatr. Hematol. 2009, 31, 462–463. Available online: https://pubmed.ncbi.nlm.nih.gov/19648798/ (accessed on 18 May 2022). [CrossRef]
7. Jabr, F.I.; Aoun, E.; Yassine, H.; Azar, C.; Taher, A. β-thalassemia intermedia and Hodgkin lymphoma. Am. J. Hematol. 2006, 81, 151. Available online: https://pubmed.ncbi.nlm.nih.gov/16432853/ (accessed on 18 May 2022). [CrossRef] [PubMed]
8. Ahad Aziz Qureshi, P.A.; Razi, M.; Rehman, A.; Hassan, A. Hodgkin lymphoma with co-existing extramedullary haematopoiesis in a Thalasaemia Major patient: Killing two birds with one stone using PET-CT. J. Pak. Med. Assoc. 2019, 69, 1059. Available online: https://pubmed.ncbi.nlm.nih.gov/31983750/ (accessed on 18 May 2022).
9. Tozzi-Cecchetti, M.C.; D’Amelio, R.; Baroni, C.D. Thalassemia major terminating in a non-Hodgkin B-cell lymphoma: Report of a case. Tumori 1979, 65, 353–357. [CrossRef]
10. Schiliro, G.; Russo, A.; Marino, S.; Musumeci, S.; Russo, G. Occurrence of lymphoma with bone marrow involvement in a boy with beta+ thalassemia major. Clin. Lab. Haematol. 1979, 1, 325–328. Available online: https://pubmed.ncbi.nlm.nih.gov/544148/ (accessed on 18 May 2022). [CrossRef]
11. O’rock, Z.K.; Shamseddine, A.I.; Taher, A.T. Non-Hodgkin disease in β-thalassemia major. Am. J. Hematol. 2005, 81, 62–64. Available online: https://pubmed.ncbi.nlm.nih.gov/16369971/ (accessed on 18 May 2022). [CrossRef] [PubMed]
12. Ricchi, A.; Carta, A.; Pinna, G.M.; Cirio, E.M.; Foddanu, M.; Terrosu, P.F.; Pardini, S.; Fozza, C.; Longinotti, M. Asymptomatic cardiac lymphoma in a hepatitis C virus-positive thalassemic patient. Ital. Hear. J. 2004, 5, 302–304. Available online: https://pubmed.ncbi.nlm.nih.gov/15185891/ (accessed on 18 May 2022).
13. Triantos, C.; Kourakli, A.; Kalafateli, M.; Giannakopoulou, D.; Koukias, N.; Thomopoulos, K.; Lampropoulou, P.; Bartzavali, C.; Fragopanagou, H.; Kagadis, G.C.; et al. Hepatitis C in patients with β-thalassemia major. A single-centre experience. Ann. Hematol. 2013, 92, 739–746. Available online: https://pubmed.ncbi.nlm.nih.gov/23412560/ (accessed on 18 May 2022). [CrossRef] [PubMed]
14. Chehal, A.; Loutfi, R.; Taher, A. β-thalassemia intermedia and non-Hodgkin’s lymphoma. Hemoglobin 2002, 26, 219–225. Available online: https://pubmed.ncbi.nlm.nih.gov/12403486/ (accessed on 18 May 2022). [CrossRef]
15. Tuğcu, D.; Karakaş, Z.; Gökeç, M.; Ağaoğlu, L.; Üntüvar, A.; Sarıbeyoğlu, E.; Akçay, A.; Devecioğlu, Ö. Thalassemia Intermedia and Acute Lymphoblastic Leukaemia: Is it a Coincidental Double Diagnosis? Turk. J. Hematol. 2014, 31, 311. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287036/ (accessed on 18 May 2022). [CrossRef]
34. Stahl, M.; Tallman, M.S. Differentiation syndrome in acute promyelocytic leukemia. Br. J. Haematol. 2019, 187, 157–162. Available online: https://pubmed.ncbi.nlm.nih.gov/31410848/ (accessed on 18 May 2022). [CrossRef] [PubMed]

35. Taher, A.T.; Musallam, K.M.; Cappellini, M.D. β-Thalassemias. N. Engl. J. Med. 2021, 384, 727–743. Available online: http://www.nejm.org/doi/10.1056/NEJMra2021838 (accessed on 18 May 2022). [CrossRef]

36. Eldor, A.; Rachmilewitz, E.A. The hypercoagulable state in thalassemia. Blood 2002, 99, 36–43. Available online: http://ashpublications.org/blood/article-pdf/99/1/36/1679491/b80102000036.pdf (accessed on 18 May 2022). [CrossRef]

37. Cappellini, M.D.; Poggiali, E.; Taher, A.; Musallam, K. Hypercoagulability in β-thalassemia: A status quo. Expert Rev. Hematol. 2012, 5, 505–512. Available online: https://pubmed.ncbi.nlm.nih.gov/23146054/ (accessed on 18 May 2022). [CrossRef]

38. Maia da Oliveira Silva, J.P.; Brugnerotto, A.F.; Romanello, K.S.; Teixeira, K.K.L.; Lanaro, C.; Duarte, A.S.; Costa, G.G.L.; Araújo, A.S.; Bezerra, M.A.C.; Domingos, I.F.; et al. Global gene expression reveals an increase of HMGB1 and APEXI proteins and their involvement in oxidative stress, apoptosis and inflammation pathways among beta-thalassemia intermedia and major phenotypes. Br. J. Haematol. 2019, 186, 608–619. Available online: https://pubmed.ncbi.nlm.nih.gov/31218684/ (accessed on 18 May 2022). [CrossRef]

39. Kanavaki, I.; Makrythanasis, P.; Lazaropoulou, C.; Tsironi, M.; Kattamis, A.; Rombos, I.; Papassotiriou, I. Soluble endothelial adhesion molecules and inflammation markers in patients with β-thalassemia intermedia. Blood Cells Mol. Dis. 2009, 43, 230–234. Available online: https://pubmed.ncbi.nlm.nih.gov/19654073/ (accessed on 18 May 2022). [CrossRef]

40. Butthep, P.; Rummanav, S.; Wisedpanichki, R.; Jindadamrongwech, S.; Fucharoen, S.; Bunyaratvej, A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am. J. Hematol. 2002, 70, 100–106. Available online: https://pubmed.ncbi.nlm.nih.gov/12111782/ (accessed on 18 May 2022). [CrossRef]

41. Tang, L.; Chai, W.; Ye, F.; Yu, Y.; Cao, L.; Yang, M.; Xie, M.; Yang, L. HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells. Oncotarget 2017, 8, 27314–27327. Available online: https://doi.org/10.18632/oncotarget.15432 (accessed on 18 May 2022). [CrossRef] [PubMed]

42. Di Noto, R.; Lo Pardo, C.; Schiavone, E.M.; Ferrara, E.; Manzo, C.; Vaccia, C.; Del Vecchio, L. All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Leuk. Lymphoma Infl. Healthc. 1996, 21, 201–209. Available online: https://pubmed.ncbi.nlm.nih.gov/8726400/ (accessed on 18 May 2022). [CrossRef] [PubMed]

43. De Santis, G.C.; Tamarozzi, M.D.B.; Sousa, R.B.; Moreno, S.E.; Secco, D.; Garcia, A.B.; Lima, A.S.G.; Faccioli, L.H.; Falcao, R.P.; Cunha, F.Q.; et al. Adhesion molecules and differentiation syndrome: Phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica 2007, 92, 1615–1622. Available online: https://pubmed.ncbi.nlm.nih.gov/18059984/ (accessed on 18 May 2022). [CrossRef]

44. Najmaddini, H.; Hassanshahi, G.; Ostadabrahimi, H.; Barkhordari, H.; Mashayekhi, H.; Nazari, M.; Moogooei, M.; Arababadi, Y.S.; Peighambari, F.; Karimabad, M.N. Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients. Ann. Saudi Med. 2014, 34, 122–127. Available online: https://pubmed.ncbi.nlm.nih.gov/24894780/ (accessed on 18 May 2022). [CrossRef]

45. Luesink, M.; Pennings, J.L.A.; Wissink, W.M.; Linssen, P.C.M.; Muus, P.; Pfundt, R.; de Witte, T.J.M.; van der Reijden, B.A.; Jansen, J.H. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: Triggering the differentiation syndrome. Blood 2009, 114, 5512–5521. Available online: https://pubmed.ncbi.nlm.nih.gov/19828696/ (accessed on 18 May 2022). [CrossRef]

46. Albanesi, J.; Noguera, N.; Banella, C.; Colangelo, T.; De Marinis, E.; Leone, S.; Palumbo, O.; Voso, M.; Ascenzi, P.; Nervi, C.; et al. Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells 2020, 9, 2423. Available online: https://www.mdpi.com/2073-4409/9/11/2423/html (accessed on 18 May 2022).

47. Mueller, B.U.; Pabst, T.; Fos, J.; Petkovic, V.; Fey, M.F.; Asou, N.; Buergi, U.; Tenen, D.G. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 2006, 107, 3330–3338. Available online: https://pubmed.ncbi.nlm.nih.gov/16352814/ (accessed on 18 May 2022). [CrossRef] [PubMed]

48. Buttari, B.; Profumo, E.; Caprari, P.; Massimi, S.; Sorrentino, F.; Maffei, L.; Rigano, R. Phenotypical and functional abnormalities of circulating neutrophils in patients with β-thalassemia. Ann. Hematol. 2020, 99, 2265–2277. Available online: https://pubmed.ncbi.nlm.nih.gov/32803313/ (accessed on 18 May 2022). [CrossRef]

49. Siwaponanan, P.; Siegers, J.Y.; Ghazali, R.; Ng, T.; Mccoll, B.; Ng, G.Z.W.; Sutton, P.; Wang, N.; Ooi, I.; Thiengtavor, C.; et al. Reduced PU.1 expression underlies aberrant neutrophil maturation and function in b-Thalassemia mice and patients. Blood 2017, 129, 3087–3099. Available online: https://pubmed.ncbi.nlm.nih.gov/28325862/ (accessed on 18 May 2022). [CrossRef]